Results 91 to 100 of about 127,263 (196)

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels [PDF]

, 2019
学位記番号 ...
Suga, Takayoshi, スガ, タカヨシ, 須賀, 孝慶   +2 more
core  

Glucagon-like peptide 1 [PDF]

, 2018
R. Tauber, F. H. Perschel
  +4 more sources

Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects [PDF]

Annals of Pediatric Endocrinology & Metabolism
Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity.
Kyu Sik Kim, Joon Seok Park, Hyung Jin Choi   +2 more
doaj   +1 more source

Cardiovascular Effects of Glucagon-Like Peptide 1

Mini-Reviews in Medicinal Chemistry, 2011
Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance.
Papazafiropoulou, A., Pappas, S. I., Papadogiannis, D., Tentolouris, N.   +3 more
openaire   +3 more sources

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Clinical Hypertension
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension.
Hae Young Lee, Seung-Hyun Ko, Sungjoon Park, Kyuho Kim, Song-Yi Kim, In-Jeong Cho, Eun Joo Cho, Hyeon Chang Kim, Jae-Hyeong Park, Sung Kee Ryu, Min Kyong Moon, Sang-Hyun Ihm, the Korean Society of Hypertension   +12 more
doaj   +1 more source

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core  

Glucagon-like peptide-1 and satiety [PDF]

Nature, 1997
G, van Dijk, T E, Thiele, R J, Seeley, S C, Woods, I L, Bernstein   +4 more
openaire   +2 more sources

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +1 more source

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes

Journal of Diabetes Investigation, 2023
Young Min Cho
doaj   +1 more source

Glucagon-like peptide-1 and energy homeostasis.

The Journal of nutrition, 2007
A growing body of evidence demonstrates the role of gut-derived hormones in the control of energy homeostasis. Among those intestinal signals, physiological and therapeutic interest has been drawn to glucagon-like peptide-1 (GLP-1). The main reasons are that this hormone 1) is secreted by epithelial intestinal L-cells in response to glucose and lipids,
Burcelin, Rémy, Cani, Patrice, Knauf, Claude   +2 more
openaire   +3 more sources